12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vidaza azacitidine: Phase II data

Top-line data from an investigator-initiated Phase II trial in 42 patients aged 60 years and older with untreated AML showed that once-daily 75 mg/m 2 Vidaza on days 1-7 followed by once-daily 50 mg Revlimid lenalidomide on days 8-28 of a 42-day cycle led to an ORR of 41%, with 28% of patients achieving a complete response (CR) or...

Read the full 284 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >